Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet
Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 2026 will be mostly about its upcoming Phase 2 readout. The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into Phase 3. As such, ALTITUDE-AD is the main swing factor, especially if iADRS slowing lands near management's target.
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals Q1 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer's disease pipeline.
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2025 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
